Obesity is rising in IBD populations, and GLP-1 receptor agonists may offer more than just weight control. In a series of new abstracts presented at Digestive Disease Week 2025, researchers from Mount Sinai explored GLP-1 use in IBD patients—and the results are promising. The medications were found to be safe, effective for weight loss, and even associated with improved disease remission, including in cases of perianal fistulizing Crohn’s disease.
Keep Reading
Add A Comment